November 7, 2022 07:12 AM ESTUpdated 07:40 AM
R&D

GSK re­ports PhI­II flop for BC­MA drug — rais­ing ques­tions about its fu­ture and up­ping the stakes on com­bos

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Deer­field se­cures $600M+ for third health­care ven­ture fund to seed new com­pa­nies

Ex­clu­sive: Topas claims suc­cess in ear­ly test of 'im­mune tol­er­ance' ther­a­py for celi­ac dis­ease

Ex­clu­sive: Ver­tex drops AAV gene ther­a­py re­search, tR­NA ther­a­py part­ner­ship

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times